Australia - Brazil - Canada - Chile - Croatia - Denmark - East Asia - Europe - Europe, United States - France - Germany - Greece - Iceland - India - International - Ireland - Italy - Japan - Latin America - Lebanon - Norway - Poland - Republic of Korea - Saudi Arabia - South Africa - Türkiye - United Kingdom - United States - WHO - {Related topics}

Australia

• Australian Diabetes Society
  • 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists [2025]

• Australian Family Physician
  • Pharmacotherapy for obesity [2017]

• Australian Journal of General Practice
  • Pharmacotherapy for the management of overweight and obesity [2025]
  • Glucagon-like peptide-1 receptor agonists for weight loss: Consider the case for selective pharmacotherapy [2025]
  • New anti-obesity medications: Considerations and future directions in people with concurrent eating disorders [2023]

• Australian Prescriber
  • Medicines for long-term obesity management [2022]

• Journal of Medical Internet Research
  • Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study [2026]

• Medical Journal of Australia
  • Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit? [2026]
  • Estimating Eligibility for GLP-1 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross-Sectional Analysis of National Health Survey Data [2026]

Brazil

• Archives of Endocrinology and Metabolism
  • Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM) [2024]

Canada

• Canada's Drug Agency
  • Pharmacoeconomic Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • Clinical Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • CADTH Canadian Drug Expert Committee Recommendation: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave — Bausch Health, Canada Inc.) [2020]

• Canadian Family Physician
  • Weight normativity in action: Semaglutide and obesity [2025]
  • Tirzepatide for weight loss [2025]
  • New drugs for weight loss [2025]

• Canadian Journal of Physiology and Pharmacology
  • Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications [2026]

• Canadian Journal of Public Health
  • Drivers of medicalization in the Canadian Adult Obesity Clinical Practice Guidelines [2022]

• Clinical Obesity
  • The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review [2025]

• International Journal of Obesity
  • Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective [2024]

• Obesity Canada
  • Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update [2025]

Chile

• Revista Médica de Chile
  • Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology [2026]

Croatia

• Journal of International Medical Research
  • Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia [2026]

• Medicina
  • National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017-2024 [2025]

Denmark

• Diabetes, Obesity and Metabolism
  • Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey [2026]

East Asia

• Advances in Therapy
  • Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison [2024]

Europe

• European Association for the Study of Obesity
  • Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update [2026]
  • Development of the European Association for the Study of Obesity (EASO) Grade-Based Framework on the Pharmacological Treatment of Obesity: Design and Methodological Aspects [2026]
  • Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO) [2025]
  • A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults [2025]
  • 2014 EASO Position Statement on the Use of Anti-Obesity Drugs [2015]

• European Journal of Pharmacology
  • Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data [2025]

• European Medicines Agency
  • Clinical evaluation of medicinal products used in weight control - Scientific guideline

• Pharmacology Research & Perspectives
  • Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs [2025]

Europe, United States

• Diabetes, Metabolic Syndrome and Obesity
  • The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials [2023]

• Frontiers in Endocrinology
  • Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals? [2025]

• International Journal of Obesity
  • Obesity pharmacotherapy in older adults: a narrative review of evidence [2025]

France

• Obesity Reviews
  • Delphi Consensus Among French Obesity Experts on Clinical Recommendations for Drug Prescription in Patients With Severe Obesity [2025]

Germany

• PharmacoEconomics
  • Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system [2026]
  • Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System [2026]

Greece

• Frontiers in Public Health
  • Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece [2025]

Iceland

• Pediatric Obesity
  • Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study [2026]

India

• Indian Journal of Pharmacology
  • Pharmacological management of obesity: Current landscape and emerging therapies [2026]

International

• Advances in Nutrition
  • Examining the Omission of Dietary Quality Data in Glucagon-Like Peptide 1 Clinical Trials: A Scoping Review [2025]

• American Journal of Cardiology
  • Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [2024]

• BMC Medicine
  • Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review [2016]

• BMJ
  • Weight regain after cessation of medication for weight management: systematic review and meta-analysis [2026]

• Current Obesity Reports
  • Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? [2021]

• Diabetes, Metabolic Syndrome and Obesity
  • Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis [2022]

• Diabetes, Obesity and Metabolism
  • Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies [2025]

• Diabetology & Metabolic Syndrome
  • The best drug supplement for obesity treatment: a systematic review and network meta-analysis [2021]

• Frontiers in Endocrinology
  • Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis [2025]
  • The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials [2023]

• Journal of Cosmetic Dermatology
  • Managing Aesthetic Needs in Prescription Medication-Driven Rapid Weight Loss Patients: Results of an International Consensus. The Clinician Perspective [2026]
  • Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study [2025]

• Nutrients
  • New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication [2026]

• Obesity Reviews
  • A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition [2026]
  • Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [2025]

• Pediatric Obesity
  • Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses [2024]
  • Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings [2024]

• Pharmacological Reviews
  • Emerging pharmacotherapies for obesity: A systematic review [2025]

• Primary Care Diabetes
  • The promise of tirzepatide: A narrative review of metabolic benefits [2025]

Ireland

• Association for the Study of Obesity on the Island of Ireland
  • Pharmacotherapy in Obesity Management [2022]

• Value in Health
  • A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland [2025]

Italy

• Digestive and Liver Disease
  • Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE) [2026]

• Frontiers in Endocrinology
  • Long-term GLP-1 receptor agonist therapy in obesity: expert panel recommendations for good clinical practice [2026]

Japan

• Circulation Journal
  • Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan - Insights From the PARACLETE Study [2026]

Latin America

• Obesity Reviews
  • Consensus on pharmacological treatment of obesity in Latin America [2024]

Lebanon

• Endocrinology, Diabetes & Metabolism
  • Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population [2026]

Norway

• Diabetes, Obesity and Metabolism
  • Pharmacological treatment of obesity in adults in Norway 2004-2022 [2024]

Poland

• Nutrition, Obesity & Metabolic Surgery
  • Treatment of overweight and obesity during and after a pandemic. Let’s not wait for the development of complications – new guidelines for doctors [2020]

Republic of Korea

• Journal of Global Health
  • A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication [2023]

Saudi Arabia

• Saudi Journal of Medicine & Medical Sciences
  • Saudi Healthcare Providers' Perspectives and Clinical Practice of Anti-Obesity Medications: A National Survey [2025]

• Scientific World Journal
  • Safety Evaluation of Local Weight-Gain Formulas in the Saudi Arabian Markets [2015]

South Africa

• South African Medical Journal
  • Pharmacotherapy for obesity management [2025]

Türkiye

• European Journal of Medical Research
  • Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study [2025]

United Kingdom

• Advances in Therapy
  • Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective [2025]
  • Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom [2023]

• BMC Medicine
  • Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain [2026]

• Diabetes, Obesity and Metabolism
  • Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases [2025]

• Health Technology Assessment
  • The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review [2025]

• Medicines and Healthcare products Regulatory Agency
  • GLP-1 medicines for weight loss and diabetes: what you need to know

• National Institute for Health and Care Excellence
  • Tirzepatide for managing overweight and obesity [2025]
  • A guide for prescribing medicines to manage overweight and obesity [2025]
  • Semaglutide for managing overweight and obesity [2023]
  • Liraglutide for managing overweight and obesity [2020]
  • Naltrexone–bupropion for managing overweight and obesity [2017]

• NHS Scotland
  • Drugs Used in the Treatment of Obesity

• PharmacoEconomics
  • Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity [2025]

• Society for Endocrinology
  • Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP-1 Agonists and Thyroid Cancer [2026]

United States

• AMA Journal of Ethics
  • Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI? [2023]

• American College of Lifestyle Medicine
  • Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society [2025]

• American College of Physicians
  • Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026) [2026]

• American Diabetes Association
  • Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity [2026]

• American Family Physician
  • Semaglutide (Wegovy) for the Treatment of Obesity [2023]

• American Gastroenterological Association
  • AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity [2022]

• American Journal of Clinical Nutrition
  • Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts-a report from the 25th Annual Harvard Nutrition Obesity Symposium [2025]

• American Journal of Health Promotion
  • The Critical Role of Lifestyle With the Use of Contemporary Obesity Management Medications [2025]
  • Building Comprehensive Care Networks to Support Lifestyle Change in Patients Taking Obesity Management Medications [2025]

• American Journal of Managed Care
  • Medication use for patients with obesity: trends and characteristics for US employees [2026]
  • Understanding insurance coverage policies for incretin mimetics for weight management [2025]

• Cardiovascular Drugs and Therapy
  • US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events [2025]
  • US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events [2025]

• Centers for Disease Control and Prevention
  • Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023 [2025]

• Cleveland Clinic Journal of Medicine
  • Update on antiobesity pharmacotherapy in adults: Current and emerging options [2026]
  • Pharmacotherapy for obesity: What you need to know [2017]

• Current Opinion in Endocrinology, Diabetes and Obesity
  • Pharmacotherapy in Pediatric Obesity: Current Evidence and Landscape [2021]

• Current Opinion in Pediatrics
  • Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice [2025]

• Diabetes Technology and Obesity Medicine
  • Artificial Intelligence-Driven Prediction of Glucagon-Like-Peptide-1 Receptor Agonist Eligibility in Obesity [2025]

• EClinicalMedicine
  • Pharmacotherapy of obesity: an update on the available medications and drugs under investigation [2023]

• Endocrine Practice
  • Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015–2018 [2021]

• Endocrine Society
  • Pharmacological management of obesity: an Endocrine Society clinical practice guideline [2015]
  • Pharmacological Management of Obesity Guideline Resources

• Endotext
  • Pharmacologic Treatment of Overweight and Obesity in Adults

• Expert Opinion on Drug Safety
  • The risk of cardiovascular complications with current obesity drugs [2020]

• Expert Opinion on Pharmacotherapy
  • The limits and challenges of antiobesity pharmacotherapy [2020]
  • Anorectic state of obesity medications in the United States. Are leaner times ahead? [2020]

• Food and Drug Administration
  • Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction [2025]

• Frontiers in Endocrinology
  • A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways [2025]

• Institute for Clinical and Economic Review
  • Obesity Management

• JAMA
  • Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis [2016]

• JAMA Health Forum
  • Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults [2025]

• JAMA Network Open
  • Older Adults' Views on Insurance Coverage for Weight Management Medications [2025]
  • Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents [2023]

• Journal of Comparative Effectiveness Research
  • Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US [2025]

• Journal of Endocrinological Investigation
  • Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study [2026]

• Journal of General Internal Medicine
  • Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform [2024]

• Journal of Managed Care & Specialty Pharmacy
  • Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States [2025]
  • Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States [2022]

• Journal of Medical Economics
  • Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial [2026]

• Journal of Racial and Ethnic Health Disparities
  • Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey [2026]

• Journal of the American Heart Association
  • State-Level Variation in Glucagon-Like Peptide-1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023 [2025]

• Journal of the Endocrine Society
  • An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal [2023]

• Journal of Women's Health
  • Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists [2021]

• Medical Surveillance Monthly Report
  • Weight loss medication prescription prevalence in the active component, 2018-2023 [2024]

• Methodist DeBakey Cardiovascular Journal
  • Medical Management of Obesity: Current Trends and Future Perspectives [2025]

• National Academies of Sciences, Engineering, and Medicine
  • Medications and Obesity: Exploring the Landscape and Advancing Comprehensive Care: Proceedings of a Workshop [2024]

• Nutrition & Diabetes
  • An algorithm for the use of anti-obesity medications [2024]

• Obesity
  • Titration and discontinuation of semaglutide for weight management in commercially insured US adults [2025]
  • Antiobesity Medications for Older Adults-the New, the Good, the Bad, and the Unknown [2025]
  • Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010 [2015]

• Obesity Medicine Association
  • Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 [2022]
  • Top Weight Loss Medications

• Obesity Pillars
  • Clinical review: Guide to pharmacological management in pediatric obesity medicine [2023]

• Obesity Society
  • Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach [2026]

• Population Health Management
  • Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE Study [2025]

• StatPearls
  • Pharmacologic Therapy for Obesity
  • Orlistat

• Turkish Journal of Medical Sciences
  • Paradigm shift in obesity treatment: an extensive review of current pipeline agents [2025]

• U.S. Department of Health and Human Services - Office of the Assistant Secretary for Planning and Evaluation
  • Medicare Coverage of Anti-Obesity Medications [2024]

WHO

• World Health Organization
  • World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults [2026]
  • GLP1-receptor agonists landscape: manufacturer mapping and regulatory pathways [2026]

{Related topics}

• Topic
  • Obesity: prevention, treatment
  • Obesity in children and adolescents: prevention, treatment
  • Obesity